Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00041288
- Locations
- ๐บ๐ธ
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
๐บ๐ธSimmons Cancer Center - Dallas, Dallas, Texas, United States
๐บ๐ธUniversity of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
- Locations
- ๐บ๐ธ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00027573
- Locations
- ๐บ๐ธ
CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale, Arizona, United States
๐บ๐ธCCOP - Oklahoma, Tulsa, Oklahoma, United States
๐บ๐ธIndiana University Cancer Center, Indianapolis, Indiana, United States
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT00028600
- Locations
- ๐บ๐ธ
Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
๐บ๐ธUnion Hospital Cancer Program at Union Hospital, Elkton MD, Maryland, United States
๐บ๐ธCCOP - Christiana Care Health Services, Newark, Delaware, United States
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: imatinib mesylateDrug: methotrexateDrug: vincristine sulfateDrug: leucovorin calciumProcedure: peripheral blood stem cell transplantationProcedure: autologous hematopoietic stem cell transplantationProcedure: allogeneic hematopoietic stem cell transplantationRadiation: total-body irradiationDrug: tacrolimusBiological: filgrastimDrug: etoposideDrug: cyclophosphamideDrug: cytarabineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00039377
- Locations
- ๐บ๐ธ
Great Falls Clinic, Great Falls, Montana, United States
๐บ๐ธMason District Hospital, Havana, Illinois, United States
๐บ๐ธBerdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaChildhood Burkitt LymphomaCutaneous B-cell Non-Hodgkin Lymphomade Novo Myelodysplastic SyndromesRecurrent Grade 1 Follicular LymphomaSmall Intestine LymphomaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Anaplastic Large Cell LymphomaChildhood Myelodysplastic Syndromes
- Interventions
- Drug: cyclophosphamideDrug: fludarabine phosphateDrug: tacrolimusDrug: mycophenolate mofetilGenetic: polymerase chain reactionGenetic: fluorescence in situ hybridizationGenetic: polymorphism analysisGenetic: gene expression analysisRadiation: total-body irradiationProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00049504
- Locations
- ๐บ๐ธ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 4
- Registration Number
- NCT00006747
- Locations
- ๐บ๐ธ
University of Chicago Cancer Research Center, Chicago, Illinois, United States
๐บ๐ธUniversity of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
๐บ๐ธUniversity of Illinois at Chicago, Chicago, Illinois, United States
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
- Conditions
- Interventions
- Drug: F-18 FluorodeoxyglucoseBiological: therapeutic allogeneic lymphocytesProcedure: Peripheral Blood Stem Cell donationDrug: cyclophosphamideDrug: cyclosporineDrug: doxorubicin hydrochlorideDrug: etoposideDrug: fludarabine phosphateDrug: melphalanDrug: prednisoneDrug: sirolimusDrug: tacrolimusDrug: vincristine sulfateProcedure: peripheral blood stem cell transplantationDrug: Filgrastim
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00043979
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 830
- Registration Number
- NCT00038948
Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Once Daily Versus Twice Daily Dosing
- Conditions
- First Posted Date
- 2001-12-18
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00028171
- Locations
- ๐บ๐ธ
Washington University/Barnes Jewish Hospital, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.